Par Drugs and Chemicals Management
Management criteria checks 4/4
Par Drugs and Chemicals' CEO is Jignesh Savani, appointed in Nov 2023, has a tenure of 2.33 years. total yearly compensation is ₹5.19M, comprised of 99.2% salary and 0.8% bonuses, including company stock and options. directly owns 42.36% of the company’s shares, worth ₹463.31M. The average tenure of the management team and the board of directors is 7.3 years and 7.2 years respectively.
Key information
Jignesh Savani
Chief executive officer
₹5.2m
Total compensation
| CEO salary percentage | 99.23% |
| CEO tenure | 2.3yrs |
| CEO ownership | 42.4% |
| Management average tenure | 7.3yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Investors Don't See Light At End Of Par Drugs and Chemicals Limited's (NSE:PAR) Tunnel
Feb 12
Par Drugs and Chemicals' (NSE:PAR) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 21The Market Doesn't Like What It Sees From Par Drugs and Chemicals Limited's (NSE:PAR) Earnings Yet As Shares Tumble 26%
Feb 19Earnings Working Against Par Drugs and Chemicals Limited's (NSE:PAR) Share Price Following 26% Dive
Dec 20There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise
Oct 29Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified
Apr 16Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Apr 05Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?
Nov 03If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity
May 19Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?
Mar 17Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?
Oct 22Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings
Aug 11Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching
Jul 14Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?
Mar 31Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?
Mar 05Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)
Feb 06
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Jan 10How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | ₹139m |
| Sep 30 2025 | n/a | n/a | ₹97m |
| Jun 30 2025 | n/a | n/a | ₹142m |
| Mar 31 2025 | ₹5m | ₹5m | ₹134m |
| Dec 31 2024 | n/a | n/a | ₹154m |
| Sep 30 2024 | n/a | n/a | ₹183m |
| Jun 30 2024 | n/a | n/a | ₹146m |
| Mar 31 2024 | ₹5m | ₹5m | ₹145m |
| Dec 31 2023 | n/a | n/a | ₹142m |
| Sep 30 2023 | n/a | n/a | ₹127m |
| Jun 30 2023 | n/a | n/a | ₹115m |
| Mar 31 2023 | ₹5m | n/a | ₹113m |
| Dec 31 2022 | n/a | n/a | ₹103m |
| Sep 30 2022 | n/a | n/a | ₹106m |
| Jun 30 2022 | n/a | n/a | ₹91m |
| Mar 31 2022 | ₹5m | ₹5m | ₹92m |
| Dec 31 2021 | n/a | n/a | ₹112m |
| Sep 30 2021 | n/a | n/a | ₹112m |
| Jun 30 2021 | n/a | n/a | ₹115m |
| Mar 31 2021 | ₹4m | ₹4m | ₹116m |
| Dec 31 2020 | n/a | n/a | ₹88m |
| Sep 30 2020 | n/a | n/a | ₹83m |
| Jun 30 2020 | n/a | n/a | ₹65m |
| Mar 31 2020 | ₹4m | n/a | ₹48m |
Compensation vs Market: Jignesh's total compensation ($USD56.31K) is about average for companies of similar size in the Indian market ($USD45.66K).
Compensation vs Earnings: Jignesh's compensation has been consistent with company performance over the past year.
CEO
Jignesh Savani (48 yo)
Mr. Jignesh Vallabhbhai Savani is Promoter of at Par Drugs and Chemicals Limited and has been its Chief Executive Officer since November 26, 2018 and serves as its Executive Director since February 26, 199...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & MD | 27.1yrs | ₹5.22m | 21.5% ₹ 235.2m | |
| CEO & Executive Director | 2.3yrs | ₹5.19m | 42.36% ₹ 463.3m | |
| Chief Financial Officer | 7.3yrs | ₹677.00k | no data | |
| Company Secretary & Compliance Officer | 7.5yrs | ₹729.00k | no data |
Experienced Management: PAR's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & MD | 27.1yrs | ₹5.22m | 21.5% ₹ 235.2m | |
| CEO & Executive Director | 27.1yrs | ₹5.19m | 42.36% ₹ 463.3m | |
| Lead Independent Director | 7.2yrs | ₹1.30m | no data | |
| Non- Executive Independent Director | 7.2yrs | ₹65.00k | no data | |
| Non- Executive Independent Director | 7.2yrs | ₹100.00k | no data | |
| Non-Executive Independent Director | 5.5yrs | ₹45.00k | no data |
Experienced Board: PAR's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 02:24 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Par Drugs and Chemicals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.